Genmab A/S (NASDAQ:GMAB) Receives Consensus Rating of “Hold” from Analysts

Genmab A/S (NASDAQ:GMAB) has received a consensus rating of “Hold” from the thirteen analysts that are presently covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and eight have given a buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $45.20.

A number of equities research analysts have issued reports on the stock. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Genmab A/S in a report on Tuesday, August 20th. BTIG Research increased their price objective on Genmab A/S from $46.00 to $47.00 and gave the company a “buy” rating in a research note on Thursday, June 27th. Morgan Stanley reissued an “equal weight” rating and set a $31.00 target price on shares of Genmab A/S in a research note on Wednesday, September 4th. Truist Financial reduced their price target on Genmab A/S from $53.00 to $50.00 and set a “buy” rating on the stock in a research report on Monday. Finally, HC Wainwright reissued a “buy” rating and set a $50.00 price objective on shares of Genmab A/S in a research report on Tuesday, August 27th.

Hedge Funds Weigh In On Genmab A/S

Several hedge funds have recently added to or reduced their stakes in GMAB. SG Americas Securities LLC boosted its holdings in shares of Genmab A/S by 360.5% in the 1st quarter. SG Americas Securities LLC now owns 29,500 shares of the company’s stock valued at $882,000 after buying an additional 23,094 shares in the last quarter. Harding Loevner LP boosted its stake in Genmab A/S by 2.7% in the fourth quarter. Harding Loevner LP now owns 3,289,895 shares of the company’s stock valued at $97,569,000 after acquiring an additional 85,665 shares in the last quarter. Capital International Investors boosted its stake in Genmab A/S by 7.8% in the first quarter. Capital International Investors now owns 4,373,277 shares of the company’s stock valued at $130,805,000 after acquiring an additional 315,355 shares in the last quarter. Aigen Investment Management LP purchased a new position in shares of Genmab A/S during the fourth quarter worth about $1,143,000. Finally, Envestnet Portfolio Solutions Inc. increased its position in shares of Genmab A/S by 2.3% during the first quarter. Envestnet Portfolio Solutions Inc. now owns 27,755 shares of the company’s stock worth $830,000 after purchasing an additional 633 shares in the last quarter. 7.07% of the stock is currently owned by hedge funds and other institutional investors.

Genmab A/S Stock Up 0.1 %

GMAB opened at $27.50 on Wednesday. Genmab A/S has a 52 week low of $24.53 and a 52 week high of $38.80. The business has a fifty day simple moving average of $27.16 and a 200-day simple moving average of $28.10. The firm has a market cap of $18.19 billion, a P/E ratio of 22.92, a P/E/G ratio of 0.87 and a beta of 0.99.

Genmab A/S (NASDAQ:GMAB) last released its earnings results on Thursday, August 8th. The company reported $0.22 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.07). The firm had revenue of $779.50 million during the quarter, compared to analyst estimates of $734.60 million. Genmab A/S had a net margin of 29.06% and a return on equity of 17.48%. Sell-side analysts expect that Genmab A/S will post 1.21 earnings per share for the current year.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.